1. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
- Author
-
Christine M. Bestvina, MD, Jennifer G. Whisenant, PhD, Valter Torri, MD, Alessio Cortellini, MD, Heather Wakelee, MD, Solange Peters, MD, PhD, Elisa Roca, MD, PhD, Alessandro De Toma, MD, Fred R. Hirsch, MD, Hirva Mamdani, MD, Balazs Halmos, MD, Oscar Arrieta, MD, Anne-Cecile Metivier, MD, Mary J. Fidler, MD, Jacobo Rogado, MD, Carolyn J. Presley, MD, MHS, Celine Mascaux, MD, Carlo Genova, MD, PhD, Juan Bautista Blaquier, MD, Alfredo Addeo, MD, Giovanna Finocchiaro, MD, Hina Khan, MD, Julien Mazieres, MD, PhD, Floriana Morgillo, MD, PhD, Jair Bar, MD, Avinash Aujayeb, MBBS, Giannis Mountzios, MD, PhD, Vieri Scotti, MD, Federica Grosso, MD, Erica Geraedts, MD, Ardak N. Zhumagaliyeva, MD, PhD, Leora Horn, MD, Marina Chiara Garassino, MD, and Javier Baena, MD
- Subjects
COVID-19 ,Cancer ,Thoracic ,NSCLC ,TERAVOLT ,Registry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
- Published
- 2022
- Full Text
- View/download PDF